Optimisation of Mechanical Insufflation:Exsufflation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-19

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with neuromuscular diseases (NMD) can suffer from a range of respiratory problems due to respiratory muscle weakness. Cough muscle weakness means secretion clearance from the airways can be problematic, a source of infection, and importantly a cause of death, in this patient group. Therefore, these patients are often supported with devices to aid clearance, such as mechanical insufflation-exsufflation (MIE). Although evidence supports the use of these devices, the optimal technique or settings on the device are not clear. Increasingly, higher pressures are used during MIE and recent work has demonstrated that there may be a physiological benefit to this. However, higher pressures increase the risk of causing lung collapse and may cause detriment to blood flow back to the heart, which is important as NMD patients frequently have concurrent heart muscle weakness. Further, recent work has demonstrated that higher pressures can cause closure of the throat, which is counter-productive in secretion clearance.

The overall aim of this study is to investigate methods to manipulate MIE to improve secretion clearance in patients with NMD. The questions it seeks to answer are:

(i) how can we maximally improve lung recruitment during inspiration, whilst maintaining patient comfort and lower pressures (ii) what is the smallest pressure difference required in expiration to achieve an improvement in cough (iii) do these proposed changes to MIE also cause throat closure (iv) what factors do patients believe contribute to their adherence to MIE therapy?

Patients with slowly progressive or stable neuromuscular diseases will be included in the study. Participation will involve two visits to the Lane Fox Respiratory Unit, each lasting approximately four hours. Patients will be recruited from specialist neuromuscular respiratory clinics by their clinical teams.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Volume-targeted Ventilation in Patients With Neuromuscular Disease

NCT06339580

Neuromuscular Diseases

RECRUITING PHASE2

Patient Preference for Mouthpiece Ventilation

NCT03867721

Neuromuscular Diseases

COMPLETED NA

Mechanical Insufflation-Exsufflation in Preventing Post Extubation Respiratory Failure in Patient With Critical Care Neuromyopathy

NCT01931228

Acute Respiratory Insufficiency Respiratory Failure

COMPLETED NA

Patient -Ventilator Interaction in Chronic Respiratory Failure

NCT01371149

Chronic Hypercapnic Respiratory Failure Obesity Hypoventilation Syndrome Neuromuscular Disease +1 more

COMPLETED PHASE2

Optimizing Communication During Ventilation

NCT01819090

Neuromuscular Disorder Respiratory Failure

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuromuscular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Insufflation optimisation

Patient will receive different inspiratory time and expiratory time, and inspiratory flow at a fixed insufflation pressure. To determine how best to recruit lung.

Group Type EXPERIMENTAL

Insufflation

Intervention Type DEVICE

Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.

Exsufflation optimisation

Patient will receive different expiratory pressures at a fixed inspiratory pressure (optimal determine in Arm 1). To determine minimum flow bias needed to generate cPEF

Group Type EXPERIMENTAL

Exsufflation

Intervention Type DEVICE

Patients will receive different exsufflation pressures at fixed insufflation pressure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insufflation

Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.

Intervention Type DEVICE

Exsufflation

Patients will receive different exsufflation pressures at fixed insufflation pressure.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stable or slowly progressive neuromuscular disease
* Respiratory muscle weakness (FVC \<60%, snip \<60%, sleep disordered breathing)
* Clinical evidence of respiratory secretions or cough peak expiratory flow \<270 and history of lower respiratory tract infection
* Documented clinical stability by supervising clinician

Exclusion Criteria

* Rapidly progressive neuromuscular disease (such as motor neuron disease)
* Decompensated respiratory failure (pH \< 7.35)
* Pregnancy
* Aged \<18
* Change in ventilator settings in preceding 4 weeks
* Significant physical or psychiatric co-morbidity that would prevent compliance with trial protocol

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No